Screening equity debate
Open your materials, follow the steps, then turn in your work.
Argue a CER position on whether genetic screening is offered fairly across communities.
1. Open your materials
2. Start the work
Read the screening equity case brief in the course shell.
Show all 5 required steps
- Read the screening equity case brief in the course shell.
- Write two prepared questions about who gets access to genetic screening and who is left out.
- Draft a CER with a claim, two pieces of evidence, and reasoning about equity.
- In the debate, note one counterargument about cost or access.
- Post your CER and reflection in the course shell.
Lost your place? Lost your place? Find the screening equity case brief in the course shell, then pick up at your CER: you need a claim, two pieces of evidence, and reasoning about who is left out.
Check your work before submitting
- You'll be able to argue a position on screening equity with evidence.
- You'll be able to address an access-based counterargument.
3. Turn in your work
DueCheck Schoology- Hand in
- One CER on whether genetic screening is offered equitably, plus a reflection naming one cost or access counterargument.
How to submit and name your file
Use the submission route shown on today's today's page.
In Schoology, open your course and the assignment for this lesson. Attach your file, select Submit, and check that it appears in the submission.
PDF upload helpYou get two school days for every day you were absent, so this deadline moves with you.
Find this lesson's Schoology assignments
These are existing assignments for your section. Follow the directions in the assignment you are working on; this list does not add new work. Check Schoology for each deadline.
Link will not open? Open Schoology, choose your course and section, and find the title shown above.
How this lesson connects
Keep using what you learned last class: Gene therapies modify or use genetic material to change cell function, and their potential benefit must be weighed against delivery limits, immune effects, off-target changes, durability, and whether changes could be inherited. Today: Early screening lowers cost and mortality, so a test that only wealthy or well-insured patients can reach turns a medical advance into a driver of inequality.
Optional: listen or watch a unit review▸
Need help? Warm-up, timing, and directions▸
💡 Big idea: Early screening lowers cost and mortality, so a test that only wealthy or well-insured patients can reach turns a medical advance into a driver of inequality.
- 0-5Hook data comparison; frame equity debate question
- 5-20Silent read of screening equity case brief; draft two access questions
- 20-35CER draft: equity claim, two evidences, reasoning
- 35-65Structured debate: equity in screening access, pro and con
- 65-75Written reflection: state one cost or access counterargument
- 75-80Post CER and reflection to course shell
- • Hook: Show side-by-side data: breast screening rates by income quintile and five-year survival rates by same quintile.
- • Why it matters: Knowing a test exists is meaningless if you cannot access it; the synthesis unit asks you to connect molecular science to social outcome.
- • Today's structure: case brief, CER prep, structured debate, reflection.
- • Exit goal: CER and reflection posted to the course shell before the bell.
- • Genomic screening is not uniformly available: cost, geography, and insurance coverage create access gaps across income and racial groups.
- • Early detection through screening reduces treatment cost and mortality, making access gaps a issue.
- • A CER on equity must name who is excluded and provide evidence of the consequence, not just assert unfairness.
PLTW connection and today's work
Open Activity 2.2.2 Reproductive Technology in myPLTW, then review the CER rubric for the screening equity debate.
Today's stopping point: Gene-therapy unit should be at 100%; this debate opens the closing Unit 2 benchmarks.
PLTW activity titles identify the course connection. If your account will not open, use the posted materials for today and tell Mr. Mendoza. Do not mark an online activity complete unless you completed it.
Course connection
- Activity 2.2.2 Reproductive Technology
The mapping has not been confirmed inside myPLTW.
Use the turn-in directions at the top of this page. Do not create a second submission unless your teacher asks for one.
Show another explanation or a smaller first step
Need help? Choose a starting point
Lesson resources: reading, slides, and vocabulary▸
The deck carries the prior idea forward, lets you inspect an analogy, maps the rule to biology, and ends with the same evidence decision and exit ticket used on this page.
Generated from this lesson's canonical data with a red-team citation check.
Gene therapies modify or use genetic material to change cell function, and their potential benefit must be weighed against delivery limits, immune effects, changes, durability, and whether changes could be inherited.
Early screening lowers cost and mortality, so a test that only wealthy or well-insured patients can reach turns a medical advance into a driver of inequality.
A review board sorts scientific evidence, stakeholder needs, possible benefits, possible burdens, and uncertainty before choosing a policy.
- Which statements are scientific evidence?
- Which statements express a value or priority?
- Who receives the benefit and who carries the burden?
Use science to estimate consequences, then state the value judgment and tradeoff that determine the decision.
A review-board model organizes reasoning but does not make one ethical principle automatically outweigh every other principle.
- • Evidence cards map to source-backed findings.
- • Stakeholder cards map to affected people and priorities.
- • The recommendation maps to an explicit tradeoff with a named uncertainty.
Driving question: If early genetic screening cuts breast deaths but the test costs money, sits in a hospital across town, and depends on insurance, which Cleveland families never get offered it, and what happens to them because of that?
What you already know: Gene therapies modify or use genetic material to change cell function, and their potential benefit must be weighed against delivery limits, immune effects, changes, durability, and whether changes could be inherited.
New idea: Early screening lowers cost and mortality, so a test that only wealthy or well-insured patients can reach turns a medical advance into a driver of inequality.
Visual or model: F1. F1. A lesson illustration or teaching diagram for Screening equity debate. Use it with E1-E3; it is a model or context image, not experimental or patient data. What to notice: Trace the labeled testing, treatment, or biological process and identify where evidence limits the decision.
- Observe or measure the relevant feature in screening equity debate.
- Organize the observation with a stable evidence ID.
- Apply this rule: Use science to estimate consequences, then state the value judgment and tradeoff that determine the decision.
- Choose the option the evidence supports and state the limit of the conclusion.
Real biomedical example: If early genetic screening cuts breast deaths but the test costs money, sits in a hospital across town, and depends on insurance, which Cleveland families never get offered it, and what happens to them because of that?
What the evidence supports: E1-E3 and F1 support the daily take-home when the response meets the stated success criteria.
What it cannot prove: The package does not support claims beyond this lesson's or any real patient diagnosis.
- • : Identifying a disease by detecting specific DNA, RNA, or proteins in a sample, allowing precise diagnosis at the level of genes and molecules.
- • validity: How well a test or study actually measures what it claims to, so the conclusions truly reflect reality.
- • reliability: The degree to which a measurement, method, or person produces the same dependable result each time under the same conditions.
- • : A test result that signals a condition is present when it actually is not, a kind of error that can lead to needless worry or treatment.
- • : A test result that says a condition is absent when it is actually present, missing a true case.
- • : An organized roadmap of the steps, therapies, and goals a healthcare team will follow to manage or cure a patient's condition.
Use it now: Choose one decision option. Cite E1 and E3, then explain how the rule connects the evidence to your choice.
Go further, optional: The source links below are optional enrichment. Every fact required for today's local evidence decision appears in this lesson package.
A defensible biomedical decision separates scientific evidence from value judgments, identifies who may benefit or be burdened, and states the uncertainty and tradeoffs that remain.
Limit: Scientific evidence can inform the options and likely consequences, but it cannot choose a single value-neutral answer.
Use science to estimate consequences, then state the value judgment and tradeoff that determine the decision.
Limit: A review-board model organizes reasoning but does not make one ethical principle automatically outweigh every other principle.
You can argue a position on screening equity with evidence.
Limit: E3 defines the classroom product or success criterion. It is not independent scientific evidence and cannot justify a clinical or causal claim.
PLTW-GEND-2026-11-09 · Simulated classroom evidence scenario
Your role: medical interventions team member
Decision: Your team must decide what the evidence from screening equity debate supports before submitting the claim-evidence-reasoning response named on today's page.
- • Trust the clearest, most polished write-up, since a well-explained result reads like the strongest evidence.
- • Stop short of a diagnosis, because the classroom lacks the validated and that claim needs.
- • Rank each piece by its source and controls, then say how a or negative changes the plan.
Response: State one choice, cite at least two evidence IDs, explain the rule that connects them, and add one limitation. Submit it as the claim-evidence-reasoning response.
Claim ceiling: Today's evidence supports a classroom claim about screening equity debate. It cannot prove causation, diagnose a real patient, or justify action outside this room.
Reason for review: Your team must decide what the evidence from screening equity debate supports before submitting the claim-evidence-reasoning response named on today's page.
Context: A medical technology is only as good as the people it reaches, so access gaps in screening are a health outcome, not just a paperwork problem.
- • T1: Read the screening equity case brief in the course shell.
- • T2: Write two prepared questions about who gets access to genetic screening and who is left out.
- • T3: Draft a CER with a claim, two pieces of evidence, and reasoning about equity.
- • T4: In the debate, note one counterargument about cost or access.
- • T5: Post your CER and reflection in the course shell.
- • E1: A defensible biomedical decision separates scientific evidence from value judgments, identifies who may benefit or be burdened, and states the uncertainty and tradeoffs that remain.
- • E2: Use science to estimate consequences, then state the value judgment and tradeoff that determine the decision.
- • E3: You can argue a position on screening equity with evidence.
Measurements: Use only the measurements, units, graph, or counts supplied in today's task. No additional patient measurement is implied.
Figure finding: Teaching diagram for Screening equity debate. Trace the labeled testing, treatment, or biological process and identify where evidence limits the decision. This is a teaching model, not patient or experimental data.
Uncertainty: This is a composite classroom scenario. Missing history, measurements, or confirmation tests remain unknown and limit the conclusion.
Mean = sum of values / number of values. Median = middle ordered value. Range = maximum - minimum.
For 2, 4, 4, and 10: mean = 20 / 4 = 5, median = 4, and range = 10 - 2 = 8.
Mean, median, and range keep the measurement unit. Order the values before finding the median.
Calculate the requested summary for today's supplied values, then write what it reveals and what it hides.
Students often think Students assume that if a genetic test exists and works, then everyone who needs it can get it, so any gap must be the patient's own choice.. The trap: That is a trap because cost, distance to a clinic, insurance rules, and which doctors even mention the test create gaps before choice ever enters, so a working test can still leave whole communities uncovered.
Note: This is a parallel model on a different case. It shows you the CER format and depth so you can see how a strong argument is built. It does NOT answer today's screening equity prompt. Build your own claim from your own evidence.\n\nClaim: Automated external defibrillators, or AEDs, are not currently placed equitably, because the neighborhoods where cardiac arrests are most likely to be survivable often have the fewest devices nearby.\n\nEvidence 1: An AED can restart a heart during sudden cardiac arrest, but it only helps if one is within reach in the first few minutes. Studies of public AED placement show that wealthier and commercial areas, like downtown office buildings and shopping centers, tend to have far more registered devices than lower-income residential neighborhoods.\n\nEvidence 2: Survival from cardiac arrest drops by roughly 10 percent for every minute that passes before a shock is delivered. In neighborhoods where the nearest AED is blocks away, locked inside a building, or simply absent, bystanders cannot reach a device in time even when they are willing to help.\n\nReasoning: Fast defibrillation is one of the strongest predictors of surviving cardiac arrest, so when device placement follows property value and foot traffic instead of where arrests actually happen, the survival gap widens along the same lines as income and geography. The technology itself works, but a device only saves a life if it is close enough to be used before the brain is starved of oxygen. That turns an uneven placement pattern into a health equity problem, not just a logistics detail.\n\nReflection (counterargument): A fair counterpoint is cost. AEDs are expensive to buy, register, and maintain, and some argue that limited funds should go where crowds are largest so each device covers the most people. My response is that placing devices where crowds gather is reasonable, but coverage should be measured against where cardiac arrests occur and how fast help can arrive, not only against headcount, so that residential neighborhoods with real medical need are not left uncovered.
This model shows the level of evidence and organization needed to complete: Parallel model of the Unit 2 synthesis argument: a claim-evidence-reasoning paragraph taking a position on whether a life-saving health resource reaches communities fairly, plus a reflection that names one cost or access counterargument. Modeled on the placement of automated external defibrillators, NOT on the genetic screening question students must argue today.
- Write one defensible claim.
- Choose specific evidence that supports the claim.
- Explain the scientific rule that connects the evidence to the claim.
Keep the structure. Replace the question, facts, measurements, and evidence. Then recheck units, vocabulary, and whether the conclusion goes beyond the evidence.
Also due today: Post your two prepared questions about who gets access and who is left out, then post your CER and reflection in Schoology before end of block.
- CER:
- Claim, Evidence, Reasoning: make a claim, back it with evidence, explain your reasoning.
- SOP:
- Standard Operating Procedure, the exact steps to follow (especially in a lab).
- Tracker:
- Your PLTW progress log where you record completed evidence.
- myPLTW:
- The PLTW course site where you do the online activities. Find it in Clever with your Microsoft sign-in, right next to Schoology.
Tap the speaker to hear a term. Add two of these to your notebook glossary with a definition and an example in your own words.
Pick just 2 or 3 words from today and make them yours: write what each one means in your own words, name the context clue or evidence that helped, then give one example from what you actually did in Screening equity debate. Try your own words first; the glossary is there if you get stuck. This is voluntary and counts as extra credit, so keep it short.
Saved on this device. Show Mr. Mendoza or add these to your notebook glossary to claim the extra credit.
Classroom documents for this lesson are posted in Schoology. Open Clever, then Schoology, and find each one by the name shown on its card.
Use this if you were absent, got stuck, or need another pass before you submit the lesson artifact.
Placement rationale
Matched Unit 2 synthesis and by path:Medical-Interventions/Unit-2_How-to-Screen-Your-Genes; keywords:genetic counseling, screening, testing. Score 154. Visibility: student-schoology (student-facing resource; link through Schoology rather than local path).
Use this after the required lesson work when you are ready for a harder application or a deeper connection.
Placement rationale
Matched Unit 2 synthesis and by path:Medical-Interventions/Unit-2_How-to-Screen-Your-Genes; keywords:genetic counseling, screening, testing. Score 146. Visibility: student-schoology (student-facing resource; link through Schoology rather than local path).
Use this after the required lesson work when you are ready for a harder application or a deeper connection.
Placement rationale
Matched Unit 2 synthesis and by path:Medical-Interventions/Unit-2_How-to-Screen-Your-Genes; keywords:genetic counseling, screening, testing. Score 142. Visibility: student-schoology (student-facing resource; link through Schoology rather than local path).
Sign in to Clever with your district Microsoft account to open Schoology or myPLTW. Follow today's posted steps. If myPLTW will not open, use the posted alternative and tell Mr. Mendoza. Turn in your completed work through the Schoology assignment.
Practice: try a question, then check your answer▸
Claim ceiling for this check: Today's evidence supports a classroom claim about screening equity debate. It cannot prove causation, diagnose a real patient, or justify action outside this room.
A CER claims 'genetic screening is unfair.' What single thing must it add to become a real equity argument instead of an opinion?
Write an answer and pick a confidence to unlock the key.
Fast retrieval with instant answers, not the commit-then-reveal check above. Try each from memory first: write what you remember about the earlier units, then check yourself here.
Missed class or ready for more?▸
Run this before you touch the bench. It is built from the real lab procedure, so the decisions you make here are the ones you will make with the equipment in your hands.
What today's skills lead to. These are real health-science careers this course builds toward. Tap one to see, on the US Department of Labor's O*NET site, what the job actually involves, what it pays, and how fast it is growing.
Missed the live debate? Watch the linked overview and post a written CER on screening equity plus your two questions and a reflection in the PLTW course shell.
Use the submission route shown on today's today's page.
Class still runs. Complete the online activity above (it's self-guided). Need the concept taught without a teacher? Use this authoritative explainer:
MedlinePlus: How is genetic testing done and what do results mean?You've passed Unit 2, so the optional extra-credit track is open. Complete reserved-unit work from home, including virtual labs, for extra credit. Each item shows its correct submission route.
Open the extra-credit track- CompleteEvery required part of the artifact is present, nothing left blank.
- AccurateThe science and the data are correct and match the evidence.
- Scientific reasoningYou explain your claim with evidence and reasoning (CER), not just an answer.
- Professional communicationClear, organized, labeled, and written the way a clinician or scientist would.
- SubmittedGo to Schoology to turn this in. Submit one PDF. Put your first and last name in the document header. Name the file: FirstName LastName - Assignment Title - YYYY-MM-DD.pdf. If you cannot get in, see Mr. Mendoza. Do not skip the work.
This week
My Progress dashboard